GC Genome Corporation (KOSDAQ:340450)

GC Genome Statistics

Total Valuation

GC Genome has a market cap or net worth of KRW 224.68 billion.

Market Cap	224.68B
Enterprise Value	n/a

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

GC Genome has 23.65 million shares outstanding.

Current Share Class	23.65M
Shares Outstanding	23.65M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	12.46M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	8.34
PB Ratio	6.73
P/TBV Ratio	6.84
P/FCF Ratio	85.79
P/OCF Ratio	81.37
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.19, with a Debt / Equity ratio of 0.14.

Current Ratio	3.19
Quick Ratio	2.83
Debt / Equity	0.14
Debt / EBITDA	1.70
Debt / FCF	1.74
Interest Coverage	-0.61

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-1.23%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	-25.38M
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	n/a
Average Volume (20 Days)	5,789,845

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, GC Genome had revenue of KRW 26.95 billion and -332.67 million in losses. Loss per share was -17.81.

Revenue	26.95B
Gross Profit	12.18B
Operating Income	-461.00M
Pretax Income	-358.04M
Net Income	-332.67M
EBITDA	2.67B
EBIT	-461.00M
Loss Per Share	-17.81

Balance Sheet

The company has 9.08 billion in cash and 4.55 billion in debt, giving a net cash position of 4.53 billion or 191.47 per share.

Cash & Cash Equivalents	9.08B
Total Debt	4.55B
Net Cash	4.53B
Net Cash Per Share	191.47
Equity (Book Value)	33.38B
Book Value Per Share	1,687.04
Working Capital	11.00B

Cash Flow

In the last 12 months, operating cash flow was 2.76 billion and capital expenditures -142.12 million, giving a free cash flow of 2.62 billion.

Operating Cash Flow	2.76B
Capital Expenditures	-142.12M
Free Cash Flow	2.62B
FCF Per Share	110.74

Margins

Gross margin is 45.20%, with operating and profit margins of -1.71% and -1.23%.

Gross Margin	45.20%
Operating Margin	-1.71%
Pretax Margin	-1.33%
Profit Margin	-1.23%
EBITDA Margin	9.92%
EBIT Margin	-1.71%
FCF Margin	9.72%

Dividends & Yields

GC Genome does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-0.15%
FCF Yield	1.17%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

GC Genome has an Altman Z-Score of 0.74 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.74
Piotroski F-Score	2